The Food and Drug Administration yesterday released comparative performance data for 55 COVID-19 molecular diagnostic tests.

Test developers are required to assess their test’s performance against a reference panel of viral samples to receive emergency use authorization.

In the data, a lower product LoD (limit of detection) indicates a test’s ability to detect a smaller amount of viral material in a given sample, signaling a more sensitive test. FDA plans to update the data as it receives additional results to help inform laboratories, health care providers and patients about the relative performance of available tests.

In other news this week, FDA awarded a research contract to the University of Liverpool and global partners to sequence and analyze SARS-CoV-2 and other coronavirus samples to help inform the real-time performance of molecular-based diagnostics.

Related News Articles

Headline
Nearly 30 representatives yesterday urged House leaders to modify in the next COVID-19 response package impending thresholds for qualifying participants in…
Headline
The U.S. death toll from COVID-19 today surpassed 200,000, according to the Coronavirus Resource Center at Johns Hopkins University & Medicine. In a joint…
Headline
The Food and Drug Administration last week reissued its emergency use authorization for the Abbott ID NOW COVID-19 test to indicate that the product is…
Headline
The Federal Reserve Board Friday updated its FAQs on the Main Street Lending Program to clarify its expectations for nonprofit and other facilities regarding…
Headline
The AHA has launched a new webpage that houses AHA-developed tools, as well as resources from the federal government and other stakeholders related to a COVID-…
Blog
From the beginning of the COVID-19 pandemic, hospitals have kept patients safe in the face of rapidly evolving scientific evidence and daunting resource…